Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24672127,Cmax,"The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0-∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours.",Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672127/),[ng] / [ml],9.5,4115,DB00175,Pravastatin
,24672127,Tmax,"The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0-∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours.",Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672127/),h,0.8,4116,DB00175,Pravastatin
,24672127,AUC0-∞,"The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0-∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours.",Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672127/),[ng] / [-·h·ml],35.7,4117,DB00175,Pravastatin
,24672127,t1/2,"The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0-∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours.",Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672127/),h,2.7,4118,DB00175,Pravastatin
,24672127,mean residence time,"The mean (SD) Cmax was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0-∞ 35.7 (19.7) ng/mL - h; t1/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours.",Pharmacokinetic properties of pravastatin in Mexicans: An open-label study in healthy adult volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672127/),h,3.1,4119,DB00175,Pravastatin
,28686078,AUC0-∞,Non-exposed animals showed AUC0-∞ of 726.0 (261.8) ng h/mL for pravastatin and rats exposed to toluene 85 mg/m3 showed AUC0-∞ of 681.8 (80.1) ng h/mL [data presented as mean (standard error of the mean)].,Effect of inhalation exposure to toluene on the activity of organic anion transporting polypeptide (Oatp) using pravastatin as a probe drug in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28686078/),[h·ng] / [ml],726.0,4142,DB00175,Pravastatin
,28686078,AUC0-∞,Non-exposed animals showed AUC0-∞ of 726.0 (261.8) ng h/mL for pravastatin and rats exposed to toluene 85 mg/m3 showed AUC0-∞ of 681.8 (80.1) ng h/mL [data presented as mean (standard error of the mean)].,Effect of inhalation exposure to toluene on the activity of organic anion transporting polypeptide (Oatp) using pravastatin as a probe drug in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28686078/),[h·ng] / [ml],681.8,4143,DB00175,Pravastatin
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,714,8258,DB00175,Pravastatin
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,256,8259,DB00175,Pravastatin
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1534,8260,DB00175,Pravastatin
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1713,8261,DB00175,Pravastatin
,16572920,Cmax,"Mean values of the individual Cmax were 126.73 +/- 61.99 ng/mL and 123.52 +/- 52.78 ng/mL for the test and reference, spectively.","Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[ng] / [ml],126.73,15218,DB00175,Pravastatin
,16572920,Cmax,"Mean values of the individual Cmax were 126.73 +/- 61.99 ng/mL and 123.52 +/- 52.78 ng/mL for the test and reference, spectively.","Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[ng] / [ml],123.52,15219,DB00175,Pravastatin
,16572920,total area under the curve up to the last measurable concentration (AUClast),Mean +/- SD total area under the curve up to the last measurable concentration (AUClast) was 224.26 +/- 104.74 ng x h/mL for the test formulation and 216.55 +/- 80.30 ng x h/mL for the reference formulation.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[h·ng] / [ml],224.26,15220,DB00175,Pravastatin
,16572920,total area under the curve up to the last measurable concentration (AUClast),Mean +/- SD total area under the curve up to the last measurable concentration (AUClast) was 224.26 +/- 104.74 ng x h/mL for the test formulation and 216.55 +/- 80.30 ng x h/mL for the reference formulation.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[h·ng] / [ml],216.55,15221,DB00175,Pravastatin
,16572920,total area under the curve (AUCinf),Mean +/- SD total area under the curve (AUCinf) was 226.72 +/- 104.69 ng x h/mL for the test formulation and 218.81 +/- 79.95 ng x h/mL for the reference.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[h·ng] / [ml],226.72,15222,DB00175,Pravastatin
,16572920,total area under the curve (AUCinf),Mean +/- SD total area under the curve (AUCinf) was 226.72 +/- 104.69 ng x h/mL for the test formulation and 218.81 +/- 79.95 ng x h/mL for the reference.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),[h·ng] / [ml],218.81,15223,DB00175,Pravastatin
,16572920,Terminal elimination half-life,Terminal elimination half-life was 2.15 +/- 0.85 h for test and 1.97 +/- 0.54 h for the reference.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),h,2.15,15224,DB00175,Pravastatin
,16572920,Terminal elimination half-life,Terminal elimination half-life was 2.15 +/- 0.85 h for test and 1.97 +/- 0.54 h for the reference.,"Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16572920/),h,1.97,15225,DB00175,Pravastatin
,12579879,limit of detection,The limit of detection for pravastatin was 13 ng.,[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),ng,13,20520,DB00175,Pravastatin
,12579879,signal-to-noise ratio,"mL-1 (signal-to-noise ratio of 3), and the limit of quantification for pravastatin in liver homogenate was 50 ng.g-1 liver (RSD < 20%).",[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),,3,20521,DB00175,Pravastatin
,12579879,extraction recovery,"The average extraction recovery of pravastatin from liver at different concentrations was 80.8%, and the average inter-day precision was 11%.",[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),%,80.8,20522,DB00175,Pravastatin
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,72,24500,DB00175,Pravastatin
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,24,24501,DB00175,Pravastatin
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,28,24502,DB00175,Pravastatin
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,4,24503,DB00175,Pravastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.33,24850,DB00175,Pravastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,2.3,24851,DB00175,Pravastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.017,24852,DB00175,Pravastatin
,31167814,IC50,"Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.064,24853,DB00175,Pravastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,0.036,24854,DB00175,Pravastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,14,24855,DB00175,Pravastatin
,31167814,IC50,"Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively.",Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31167814/),μM,1.3,24856,DB00175,Pravastatin
,12942850,elimination half-life,"It is mainly eliminated in the faeces, with an elimination half-life in humans of between 13 and 21 hours.","[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942850/),h,13 and 21,26698,DB00175,Pravastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB00175,Pravastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB00175,Pravastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB00175,Pravastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB00175,Pravastatin
,2125605,AUC0-24,"The systemic bioavailabilities of total (active plus potentially active) inhibitors for the two drugs were different, with the mean AUC value for lovastatin being 50% higher than that of pravastatin (mean +/- SEM AUC0-24 values of 285 +/- 25 and 189 +/- 13 ng-equiv x hr/mL, respectively, P less than .0001).",Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125605/),[h·ng-equiv] / [ml],285,29816,DB00175,Pravastatin
,2125605,AUC0-24,"The systemic bioavailabilities of total (active plus potentially active) inhibitors for the two drugs were different, with the mean AUC value for lovastatin being 50% higher than that of pravastatin (mean +/- SEM AUC0-24 values of 285 +/- 25 and 189 +/- 13 ng-equiv x hr/mL, respectively, P less than .0001).",Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125605/),[h·ng-equiv] / [ml],189,29817,DB00175,Pravastatin
,30335192,Cmax ratios,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.01-2.05,33112,DB00175,Pravastatin
,30335192,AUC ratio,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.04-2.23,33113,DB00175,Pravastatin
,30335192,Cmax ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33114,DB00175,Pravastatin
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33115,DB00175,Pravastatin
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.41,33116,DB00175,Pravastatin
,29388346,Jmax,The active hepatic uptake of pravastatin was determined with a Jmax value of 134.4 pmol/min/million cells and Km of 76.77 µM in plateable human hepatocytes with human plasma.,Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29388346/),[pM] / [cells·million·min],134.4,37958,DB00175,Pravastatin
,29388346,Km,The active hepatic uptake of pravastatin was determined with a Jmax value of 134.4 pmol/min/million cells and Km of 76.77 µM in plateable human hepatocytes with human plasma.,Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29388346/),μM,76.77,37959,DB00175,Pravastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB00175,Pravastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB00175,Pravastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB00175,Pravastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB00175,Pravastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB00175,Pravastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB00175,Pravastatin
,9403282,accumulation index,"SQ 31,945, the inactive polar metabolite, did accumulate in dialysis patients, as evidenced by an accumulation index of 1.7 +/- 1.0.",The pharmacokinetics of pravastatin in patients on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403282/),,1.7,55241,DB00175,Pravastatin
,9403282,dialytic clearance,"Although metabolic clearance is the predominant mode of elimination of pravastatin, hemodialysis clearances of pravastatin, SQ 31,906 and SQ 31,945 will contribute to total body clearance since dialytic clearance ranged from 40 to 80 ml.min-1.",The pharmacokinetics of pravastatin in patients on chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403282/),[ml] / [min],40 to 80,55242,DB00175,Pravastatin
,11020028,Peak plasma concentrations,Peak plasma concentrations of pravastatin were found between 60 min and 120 min after oral administration of 60 mg and reached values between 37 microg/l and 126 microg/l.,Determination of pravastatin by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[μg] / [l],37,56797,DB00175,Pravastatin
,11020028,Peak plasma concentrations,Peak plasma concentrations of pravastatin were found between 60 min and 120 min after oral administration of 60 mg and reached values between 37 microg/l and 126 microg/l.,Determination of pravastatin by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[μg] / [l],126,56798,DB00175,Pravastatin
,11020028,AUCs,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[ng] / [h·ml],52,56799,DB00175,Pravastatin
,11020028,AUCs,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[ng] / [h·ml],311,56800,DB00175,Pravastatin
,11020028,plasma elimination half-life times,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),min,95,56801,DB00175,Pravastatin
,11020028,plasma elimination half-life times,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),min,165,56802,DB00175,Pravastatin
,2106337,oral absorption,"The oral absorption of [14C] activity from pravastatin sodium was about 34% and the oral bioavailability was about 18%, suggesting first-pass metabolism of pravastatin.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),%,34,57706,DB00175,Pravastatin
,2106337,oral bioavailability,"The oral absorption of [14C] activity from pravastatin sodium was about 34% and the oral bioavailability was about 18%, suggesting first-pass metabolism of pravastatin.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),%,18,57707,DB00175,Pravastatin
,2106337,recovery of radioactivity,"After the intravenous dose, the recovery of radioactivity averaged 60% and 34% in urine and faeces, respectively.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),%,60,57708,DB00175,Pravastatin
,2106337,recovery of radioactivity,"After the intravenous dose, the recovery of radioactivity averaged 60% and 34% in urine and faeces, respectively.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),%,34,57709,DB00175,Pravastatin
,2106337,plasma elimination half-life,"The estimated average plasma elimination half-life of pravastatin was 0.8 and 1.8 h for the intravenous and oral routes, respectively.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),h,0.8,57710,DB00175,Pravastatin
,2106337,plasma elimination half-life,"The estimated average plasma elimination half-life of pravastatin was 0.8 and 1.8 h for the intravenous and oral routes, respectively.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),h,1.8,57711,DB00175,Pravastatin
,2106337,total,"The average values for total and renal clearances were 13.5 and 6.3 ml min-1 kg-1, respectively, and the steady-state volume of distribution averaged 0.51 kg-1.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),[ml] / [kg·min],13.5,57712,DB00175,Pravastatin
,2106337,renal clearances,"The average values for total and renal clearances were 13.5 and 6.3 ml min-1 kg-1, respectively, and the steady-state volume of distribution averaged 0.51 kg-1.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),[ml] / [kg·min],6.3,57713,DB00175,Pravastatin
,2106337,steady-state volume of distribution,"The average values for total and renal clearances were 13.5 and 6.3 ml min-1 kg-1, respectively, and the steady-state volume of distribution averaged 0.51 kg-1.","Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2106337/),1/[kg],0.51,57714,DB00175,Pravastatin
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],101,61552,DB00175,Pravastatin
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],2 540,61553,DB00175,Pravastatin
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],23 900,61554,DB00175,Pravastatin
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],249,63881,DB00175,Pravastatin
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],241,63882,DB00175,Pravastatin
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],243,63883,DB00175,Pravastatin
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],459,63884,DB00175,Pravastatin
,12811365,nonrenal clearance,"Subjects with the OATP-C*15 allele (Asp130Ala174) had a reduced total and nonrenal clearance, as compared with those with the OATP-C*1b allele (Asp130Val174); nonrenal clearance values in *1b/*1b (n = 4), *1b/*15 (n = 9), and *15/*15 (n = 1) subjects were 2.01 +/- 0.42 L. kg(-1).",Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811365/),[l] / [kg],2.01,67342,DB00175,Pravastatin
,29403744,flow rate,"The reconstituted samples were chromatographed on a Zorbax SB-C18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),[ml] / [min],0.8,67953,DB00175,Pravastatin
,29403744,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),min,2.0,67954,DB00175,Pravastatin
<,11558544,elimination half-life,"Unusual pharmacokinetic profiles were obtained, including high binding percentage with plasma protein (> 99%), a short elimination half-life (< 4 hr) and a relatively large Vd-area (0.5 L/kg).",Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558544/),h,4,73265,DB00175,Pravastatin
,11558544,Vd-area,"Unusual pharmacokinetic profiles were obtained, including high binding percentage with plasma protein (> 99%), a short elimination half-life (< 4 hr) and a relatively large Vd-area (0.5 L/kg).",Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558544/),[l] / [kg],0.5,73266,DB00175,Pravastatin
,11558544,recovery,The recovery of FNX from urine was approximately 9 % of the dose within 24 hr following the injection.,Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11558544/),%,9,73267,DB00175,Pravastatin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],544,73280,DB00175,Pravastatin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],10.2,73281,DB00175,Pravastatin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],1800,73282,DB00175,Pravastatin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],298,73283,DB00175,Pravastatin
,29555827,"canalicular efflux clearance (CLint, bile)","The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],10.2,73284,DB00175,Pravastatin
,29555827,"canalicular efflux clearance (CLint, bile)","The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],298,73285,DB00175,Pravastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB00175,Pravastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB00175,Pravastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB00175,Pravastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB00175,Pravastatin
,27094305,elimination half-life,"Pravastatin sodium (PVS) is a freely water-soluble HMG-CoA inhibitor that suffers from instability at gastric pH, extensive first pass metabolism, short elimination half-life (1-3 h) and low oral bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094305/),h,1-3,80507,DB00175,Pravastatin
,27094305,oral bioavailability,"Pravastatin sodium (PVS) is a freely water-soluble HMG-CoA inhibitor that suffers from instability at gastric pH, extensive first pass metabolism, short elimination half-life (1-3 h) and low oral bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094305/),%,18,80508,DB00175,Pravastatin
,16678544,area under the plasma concentration-time curve,"The mean area under the plasma concentration-time curve of pravastatin was 110% higher (305.0 +/- 149.4 ng . h/mL [mean +/- SD] versus 144.9 +/- 48.2 ng . h/mL, P = .012) and the mean peak concentration in plasma was 231% higher (174.5 +/- 98.6 ng/mL versus 52.7 +/- 22.1 ng/mL, P = .0042) in the SLCO1B1 variant haplotype group than in the control group.",Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678544/),[h·ng] / [ml],305.0,82422,DB00175,Pravastatin
,16678544,area under the plasma concentration-time curve,"The mean area under the plasma concentration-time curve of pravastatin was 110% higher (305.0 +/- 149.4 ng . h/mL [mean +/- SD] versus 144.9 +/- 48.2 ng . h/mL, P = .012) and the mean peak concentration in plasma was 231% higher (174.5 +/- 98.6 ng/mL versus 52.7 +/- 22.1 ng/mL, P = .0042) in the SLCO1B1 variant haplotype group than in the control group.",Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678544/),[h·ng] / [ml],144.9,82423,DB00175,Pravastatin
,16678544,peak concentration,"The mean area under the plasma concentration-time curve of pravastatin was 110% higher (305.0 +/- 149.4 ng . h/mL [mean +/- SD] versus 144.9 +/- 48.2 ng . h/mL, P = .012) and the mean peak concentration in plasma was 231% higher (174.5 +/- 98.6 ng/mL versus 52.7 +/- 22.1 ng/mL, P = .0042) in the SLCO1B1 variant haplotype group than in the control group.",Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678544/),[ng] / [ml],174.5,82424,DB00175,Pravastatin
,16678544,peak concentration,"The mean area under the plasma concentration-time curve of pravastatin was 110% higher (305.0 +/- 149.4 ng . h/mL [mean +/- SD] versus 144.9 +/- 48.2 ng . h/mL, P = .012) and the mean peak concentration in plasma was 231% higher (174.5 +/- 98.6 ng/mL versus 52.7 +/- 22.1 ng/mL, P = .0042) in the SLCO1B1 variant haplotype group than in the control group.",Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678544/),[ng] / [ml],52.7,82425,DB00175,Pravastatin
,19695392,C(max),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[ng] / [ml],315.7,85082,DB00175,Pravastatin
,19695392,C(max),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[ng] / [ml],115.8,85083,DB00175,Pravastatin
,19695392,AUC(0-12),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],604.8,85084,DB00175,Pravastatin
,19695392,AUC(0-12),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],259.0,85085,DB00175,Pravastatin
,19695392,AUC(0-infinity)),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],623.3,85086,DB00175,Pravastatin
,19695392,AUC(0-infinity)),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],275.1,85087,DB00175,Pravastatin
,19695392,apparent oral clearance (CL/F),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[l] / [h·kg],0.52,85088,DB00175,Pravastatin
,19695392,apparent oral clearance (CL/F),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[l] / [h·kg],1.30,85089,DB00175,Pravastatin
,32590030,IC50,"Vemurafenib IC50,total values against OATP1B1 and OATP1B3 are 175 ± 82 and 231 ± 26 μM, respectively.",Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590030/),μM,175,91101,DB00175,Pravastatin
,32590030,IC50,"Vemurafenib IC50,total values against OATP1B1 and OATP1B3 are 175 ± 82 and 231 ± 26 μM, respectively.",Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590030/),μM,231,91102,DB00175,Pravastatin
,32590030,AUC ratio,"The simulated pravastatin AUC ratio was 1.28 when a single dose of pravastatin (40 mg) was co-administered with vemurafenib (960 mg, twice daily) at steady-state, compared to pravastatin alone.",Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32590030/),,1.28,91103,DB00175,Pravastatin
,16107564,systemic (total) clearance,"The mean systemic (total) clearance of pravastatin was 4.6-fold higher (39.2 versus 8.50 l/h/kg, p < 0.001) and the mean V 4.3-fold higher (14.1 versus 3.29 l/kg, p < 0.01) in the wild-type rats.",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [h·kg],39.2,100194,DB00175,Pravastatin
,16107564,systemic (total) clearance,"The mean systemic (total) clearance of pravastatin was 4.6-fold higher (39.2 versus 8.50 l/h/kg, p < 0.001) and the mean V 4.3-fold higher (14.1 versus 3.29 l/kg, p < 0.01) in the wild-type rats.",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [h·kg],8.50,100195,DB00175,Pravastatin
,16107564,V,"The mean systemic (total) clearance of pravastatin was 4.6-fold higher (39.2 versus 8.50 l/h/kg, p < 0.001) and the mean V 4.3-fold higher (14.1 versus 3.29 l/kg, p < 0.01) in the wild-type rats.",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [kg],14.1,100196,DB00175,Pravastatin
,16107564,V,"The mean systemic (total) clearance of pravastatin was 4.6-fold higher (39.2 versus 8.50 l/h/kg, p < 0.001) and the mean V 4.3-fold higher (14.1 versus 3.29 l/kg, p < 0.01) in the wild-type rats.",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [kg],3.29,100197,DB00175,Pravastatin
,16107564,renal clearance,"The mean renal clearance of pravastatin in the TR(-) rats was 16.5-fold increased as compared with the wild-type animals (0.695 versus 0.042 l/h/kg, p < 0.05).",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [h·kg],0.695,100198,DB00175,Pravastatin
,16107564,renal clearance,"The mean renal clearance of pravastatin in the TR(-) rats was 16.5-fold increased as compared with the wild-type animals (0.695 versus 0.042 l/h/kg, p < 0.05).",Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16107564/),[l] / [h·kg],0.042,100199,DB00175,Pravastatin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00175,Pravastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00175,Pravastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00175,Pravastatin
,22340111,Run time,Run time was 2 min.,Determination of pravastatin and pravastatin lactone in rat plasma and urine using UHPLC-MS/MS and microextraction by packed sorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22340111/),min,2,102051,DB00175,Pravastatin
,22340111,recovery,Method recovery was ranged within 97-109% for plasma samples and 92-101% for the urine samples.,Determination of pravastatin and pravastatin lactone in rat plasma and urine using UHPLC-MS/MS and microextraction by packed sorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22340111/),%,97-109,102052,DB00175,Pravastatin
,22340111,recovery,Method recovery was ranged within 97-109% for plasma samples and 92-101% for the urine samples.,Determination of pravastatin and pravastatin lactone in rat plasma and urine using UHPLC-MS/MS and microextraction by packed sorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22340111/),%,92-101,102053,DB00175,Pravastatin
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105879,DB00175,Pravastatin
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1084.81,105880,DB00175,Pravastatin
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105881,DB00175,Pravastatin
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1265.0,105882,DB00175,Pravastatin
,25108106,flow rate,"Separation was performed on an Agilent Zorbax SB-Aq (3.0 × 150 mm, 3.5 μm) column using a gradient elution method with acetonitrile-0.1% formic acid in water at a flow rate of 0.35 mL/min.",Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),[ml] / [min],0.35,107959,DB00175,Pravastatin
,25108106,m/z,"The deprotonated precursor to product ion transitions monitored for Nigella A and IS was at m/z 1352.7→882.6 and m/z 423.1→321.0, respectively.",Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),,1352.7,107960,DB00175,Pravastatin
,25108106,m/z,"The deprotonated precursor to product ion transitions monitored for Nigella A and IS was at m/z 1352.7→882.6 and m/z 423.1→321.0, respectively.",Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),,8,107961,DB00175,Pravastatin
,25108106,m/z,"The deprotonated precursor to product ion transitions monitored for Nigella A and IS was at m/z 1352.7→882.6 and m/z 423.1→321.0, respectively.",Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),,423.1,107962,DB00175,Pravastatin
,25108106,m/z,"The deprotonated precursor to product ion transitions monitored for Nigella A and IS was at m/z 1352.7→882.6 and m/z 423.1→321.0, respectively.",Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),,321.0,107963,DB00175,Pravastatin
,25108106,recovery,The simple extraction procedure provided recovery ranged from 92.32 to 95.44% for both analyte and IS.,Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),%,92.32,107964,DB00175,Pravastatin
,25108106,recovery,The simple extraction procedure provided recovery ranged from 92.32 to 95.44% for both analyte and IS.,Development and validation of liquid chromatography-tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25108106/),%,95,107965,DB00175,Pravastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],25,108570,DB00175,Pravastatin
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],14,108571,DB00175,Pravastatin
,22114872,K(i),"Quercetin competitively inhibited OATP1B1-mediated E3S uptake with a K(i) value of 17.9 ± 4.6 µm and also inhibited OATP1B1-mediated pravastatin uptake in a concentration dependent manner (IC(50) , 15.9 ± 1.4 µm).",Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114872/),µm,17.9,108825,DB00175,Pravastatin
,22114872,IC(50),"Quercetin competitively inhibited OATP1B1-mediated E3S uptake with a K(i) value of 17.9 ± 4.6 µm and also inhibited OATP1B1-mediated pravastatin uptake in a concentration dependent manner (IC(50) , 15.9 ± 1.4 µm).",Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114872/),µm,15.9,108826,DB00175,Pravastatin
,17703482,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 423 --> 101, 420 --> 290 and 410 --> 348 for pravastatin, pitavastatin and fluvastatin, respectively.","Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),,423,114040,DB00175,Pravastatin
,17703482,limit of detection,The limit of detection was 1 ng/mL for all analytes.,"Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),[ng] / [ml],1,114041,DB00175,Pravastatin
,15176654,tmax,The corresponding value of tmax was 0.000 (-0.250 to approximately 0.250).,Bioequivalence of pravastatin tablet formulations assessed in Korean males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176654/),,0.000,114195,DB00175,Pravastatin
,9625267,Cmax,"Cmax was 48.9 +/- 7.1 ng/ml (mean +/- SEM, n = 20), and the mean AUC0-4.5h was 104.4 ng x h/ml (n = 5) for a 20 mg daily oral dose.",A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625267/),[ng] / [ml],48.9,116405,DB00175,Pravastatin
,9625267,AUC0-4.5h,"Cmax was 48.9 +/- 7.1 ng/ml (mean +/- SEM, n = 20), and the mean AUC0-4.5h was 104.4 ng x h/ml (n = 5) for a 20 mg daily oral dose.",A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625267/),[h·ng] / [ml],104.4,116406,DB00175,Pravastatin
,9625267,Cmax,"A great interindividual variability was found for Cmax, which varied from 6.2 ng/ml to 117.8 ng/ml on the 20 mg dose.",A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625267/),[ng] / [ml],6.2,116407,DB00175,Pravastatin
,9625267,Cmax,"A great interindividual variability was found for Cmax, which varied from 6.2 ng/ml to 117.8 ng/ml on the 20 mg dose.",A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625267/),[ng] / [ml],117.8,116408,DB00175,Pravastatin
,31266752,terminal half-life,The mean terminal half-life following a single 600 mg dose was approximately 8 hours.,"GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31266752/),h,8,118587,DB00175,Pravastatin
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB00175,Pravastatin
,24070396,clearance index,"The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 ± 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 ± 0.07, P < .01).",Transplacental transfer and distribution of pravastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24070396/),,0.,132994,DB00175,Pravastatin
,26849185,flow rate,"Chromatographic separation was performed on a Cortecs™ C18 column (2.1×100mm, 1.8μm), using gradient elution with a blend of acetonitrile and 10mM methylammonium acetate buffer (pH 4.5) at a flow rate of 0.4mL/min.","Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS/MS and its application to a pediatric pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849185/),[ml] / [min],0.4,135546,DB00175,Pravastatin
,19151602,activation energy,"Permeability of montelukast has an activation energy of 13.7+/-0.7 kcal/mol, consistent with carrier-mediated transport.",Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151602/),[kcal] / [mol],13.7,138498,DB00175,Pravastatin
,19151602,maximal inhibition,"Permeability is subject to competition by sulfobromophthalein, estrone-3-sulfate, pravastatin, taurocholic acid, and cholic acid (P<0.05, percentage of control: 72+/-7-86+/-7) and is inhibited by 5-10% citrus juice (P<0.05, maximal inhibition percentage of control: 31+/-2).",Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151602/),,31,138499,DB00175,Pravastatin
,18506696,flow rate,"Chromatographic separation was achieved on a C(18) column (250 x 4.6 mm i.d., 5 microm particle size) with a mobile phase of methanol-acetonitrile-water (containing 2 mmol/L ammonium acetate; 42.5:42.5:15, v/v/v) at a flow rate of 0.4 mL/min.",Determination of sodium cromoglycate in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506696/),[ml] / [min],0.4,144475,DB00175,Pravastatin
,18506696,recovery,Ions monitored in the multiple reaction monitoring mode were m/z 469.0 (precursor ion) to m/z 245.0 (product ion) for SCG and m/z 447.2 (precursor ion) to m/z327.1 (product ion) for pravastatin sodium (internal standard) The average recovery of SCG from human plasma was 94.88% and the lower limit of quantitation was 0.3 ng/mL.,Determination of sodium cromoglycate in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506696/),%,94.88,144476,DB00175,Pravastatin
,17516697,C(max),"The C(max) in prepubertal (group A) children (52.1 +/- 27.0 mug/L [mean +/- SD]) differed, although not significantly (p = 0.09, unpaired two-tailed t-test), from the C(max) in adolescents (group B) [31.7 +/- 29.2 mug/L].",Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[μg] / [l],52.1,150876,DB00175,Pravastatin
,17516697,C(max),"The C(max) in prepubertal (group A) children (52.1 +/- 27.0 mug/L [mean +/- SD]) differed, although not significantly (p = 0.09, unpaired two-tailed t-test), from the C(max) in adolescents (group B) [31.7 +/- 29.2 mug/L].",Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[μg] / [l],31.7,150877,DB00175,Pravastatin
,17516697,AUC,The AUC in prepubertal children (91.3 +/- 39.7 mug .,Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),μg,91.3,150878,DB00175,Pravastatin
,17516697,AUC,h/L) did not differ significantly from the AUC in adolescents (69.3 +/- 57.0 mug .,Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),μg,69.3,150879,DB00175,Pravastatin
,17516697,t((1/2)),The t((1/2)) was the same for the two groups: 2.5 +/- 1.1h.,Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),h,2.5,150880,DB00175,Pravastatin
,17516697,Clearance values (CL/f),Clearance values (CL/f) varied widely between the two groups (group A: 4.3 +/- 1.8 L/min; group B: 11.0 +/- 11.9 L/min; p = 0.08).,Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[l] / [min],4.3,150881,DB00175,Pravastatin
,17516697,Clearance values (CL/f),Clearance values (CL/f) varied widely between the two groups (group A: 4.3 +/- 1.8 L/min; group B: 11.0 +/- 11.9 L/min; p = 0.08).,Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[l] / [min],11.0,150882,DB00175,Pravastatin
,17516697,volumes of distribution,"A large variation was found in the volumes of distribution within the two groups (group A: 31.2 mL/kg [SD 26.7], group B:37.0 mL/kg [SD 29.6]; p = 0.12).",Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[ml] / [kg],31.2,150883,DB00175,Pravastatin
,17516697,volumes of distribution,"A large variation was found in the volumes of distribution within the two groups (group A: 31.2 mL/kg [SD 26.7], group B:37.0 mL/kg [SD 29.6]; p = 0.12).",Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516697/),[ml] / [kg],37.0,150884,DB00175,Pravastatin
,23112426,50% inhibition concentration (IC(50)),Pravastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 14 µM.,Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112426/),μM,14,158380,DB00175,Pravastatin
,23112426,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of nimodipine with pravastatin (1 mg/kg) was 31.1%, which was significantly enhanced compared with the oral control group.",Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112426/),%,31.1,158381,DB00175,Pravastatin
,15116054,area under the plasma concentration-time curve from time 0 to 6 hours [AUC(0-6)],"Values for the area under the plasma concentration-time curve from time 0 to 6 hours [AUC(0-6)] in *1a/*1a, *1a/*1b or *1b/*1b, and *1a/*5 individuals were 114.5 +/- 68.6 microg.",Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116054/),μg,114.5,167135,DB00175,Pravastatin
,15116054,amount,"However, the amount of pravastatin excreted into the urine from time 0 to 12 hours [Ae(0-12)] was significantly diminished in the OATP-C *1b haplotype group (1729 +/- 907 microg) compared with *1a wild-type control subjects (2974 +/- 1590 microg) (P =.049).",Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116054/),μg,1729,167136,DB00175,Pravastatin
,15116054,excreted into the urine from time 0 to 12 hours [Ae(0-12),"However, the amount of pravastatin excreted into the urine from time 0 to 12 hours [Ae(0-12)] was significantly diminished in the OATP-C *1b haplotype group (1729 +/- 907 microg) compared with *1a wild-type control subjects (2974 +/- 1590 microg) (P =.049).",Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116054/),μg,1729,167137,DB00175,Pravastatin
,15116054,excreted into the urine from time 0 to 12 hours [Ae(0-12),"However, the amount of pravastatin excreted into the urine from time 0 to 12 hours [Ae(0-12)] was significantly diminished in the OATP-C *1b haplotype group (1729 +/- 907 microg) compared with *1a wild-type control subjects (2974 +/- 1590 microg) (P =.049).",Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116054/),μg,2974,167138,DB00175,Pravastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],48.0,169350,DB00175,Pravastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],14.1,169351,DB00175,Pravastatin
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],3.10,169352,DB00175,Pravastatin
,7891286,detection limit,"The detection limit was 2 pg/injection of PS, which was 20 times more sensitive than the conventional fluorescence detection.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[pg] / [injection],2,175592,DB00175,Pravastatin
,7891286,maximum concentrations,"A single oral dose of PS in rats (20 mg/kg) and dogs (5 mg/kg) resulted in average maximum concentrations of 142 and 310 ng/mL, respectively.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[ng] / [ml],142,175593,DB00175,Pravastatin
,7891286,maximum concentrations,"A single oral dose of PS in rats (20 mg/kg) and dogs (5 mg/kg) resulted in average maximum concentrations of 142 and 310 ng/mL, respectively.",Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891286/),[ng] / [ml],310,175594,DB00175,Pravastatin
,16514303,maximum plasma concentrations,"Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%.",Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16514303/),[ng] / [ml],27.9,181636,DB00175,Pravastatin
,16514303,maximum plasma concentrations,"Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%.",Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16514303/),[ng] / [ml],12.4,181637,DB00175,Pravastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,35,184743,DB00175,Pravastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,23,184744,DB00175,Pravastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,31,184745,DB00175,Pravastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184746,DB00175,Pravastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],0.943,184747,DB00175,Pravastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184748,DB00175,Pravastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,16,184749,DB00175,Pravastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],3.39,184750,DB00175,Pravastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],5.48,184751,DB00175,Pravastatin
,12891228,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 15.7 ng/mL (range, 1.6-55.0 ng/mL), and the mean time to reach C(max) was 1.4 hours (range, 0.5-4 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),[ng] / [ml],15.7,188534,DB00175,Pravastatin
,12891228,time to reach C(max),"The mean peak plasma concentration (C(max)) of pravastatin was 15.7 ng/mL (range, 1.6-55.0 ng/mL), and the mean time to reach C(max) was 1.4 hours (range, 0.5-4 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),h,1.4,188535,DB00175,Pravastatin
,12891228,elimination half-life,"The mean elimination half-life of pravastatin was 1.6 hours (range, 0.85-4.2 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),h,1.6,188536,DB00175,Pravastatin
,12891228,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of pravastatin ranged from 5.7 to 58.9 ng.,Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),ng,5.7 to 58.9,188537,DB00175,Pravastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00175,Pravastatin
,23369879,constant flow rate,"Adequate chromatographic separation was achieved using Phenomenex Synergi 4u polar-RP 80A (150mm×4.6mm, 4μm) column in the isocratic elution mode and the eluent was water/methanol (14:86%, v/v) adjusted by trichloroacetic acid to pH 3.2 which was delivered isocratically at constant flow rate of 0.50mL/min.",Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23369879/),[ml] / [min],0.50,189319,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],151,190014,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],75,190015,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],17,190016,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],548,190017,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],167,190018,DB00175,Pravastatin
,11873000,area under the curves (AUC)(0-24),"In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],289,190019,DB00175,Pravastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],24 319,190020,DB00175,Pravastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [ml],26 760,190021,DB00175,Pravastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],15 565,190022,DB00175,Pravastatin
,11873000,AUC(0-8),"In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin).",Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11873000/),[h·ng] / [m],14 571,190023,DB00175,Pravastatin
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB00175,Pravastatin
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB00175,Pravastatin
,11772327,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772327/),h,20,197177,DB00175,Pravastatin
,9653968,recovery,The recovery of pravastatin from plasma was 69.2+/-6.7% (mean+/-S.D.).,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),%,69.2,197857,DB00175,Pravastatin
,9653968,limit of detection,"The limit of detection for pravastatin in aqueous solution was 0.4 ng, the limit of quantitation in plasma was 2 ng/ml.",Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),ng,0.4,197858,DB00175,Pravastatin
,9653968,t1/2,In a preliminary pharmacokinetic study with two healthy volunteers the t1/2 of pravastatin in plasma was found to be 0.8 and 2.3 h.,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),h,0.8,197859,DB00175,Pravastatin
,9653968,t1/2,In a preliminary pharmacokinetic study with two healthy volunteers the t1/2 of pravastatin in plasma was found to be 0.8 and 2.3 h.,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),h,2.3,197860,DB00175,Pravastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB00175,Pravastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB00175,Pravastatin
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB00175,Pravastatin
,1904355,oral absorption,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,34,210347,DB00175,Pravastatin
,1904355,bioavailability,"Radiolabelled studies demonstrated oral absorption and bioavailability values of 34% and 17%, respectively.","Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,17,210348,DB00175,Pravastatin
,1904355,plasma elimination half-life,Peak blood level after oral administration is reached at approximately 1 h and the mean plasma elimination half-life is 1.8 h.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),h,1.8,210349,DB00175,Pravastatin
,1904355,Binding,Binding of total radioactivity to plasma proteins averages 45%.,"Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904355/),%,45,210350,DB00175,Pravastatin
,12769127,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12769127/),h,20,214857,DB00175,Pravastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.050,215035,DB00175,Pravastatin
,15045696,fractional catabolic rate (FCR),"Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P <.03), and there was a significant correlation between FCR and the peak LDL diameter of the injected fractions (R(2) =.71, P <.034).",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.134,215036,DB00175,Pravastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.255,215037,DB00175,Pravastatin
,15045696,"k(2,1)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.277,215038,DB00175,Pravastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.105,215039,DB00175,Pravastatin
,15045696,"k(1,2)","The sum of the equilibration parameters, k(2,1) and k(1,2), for smaller LDL (0.255 h(-1) and 0.105 h(-1), respectively) was significantly smaller than that for larger LDL (0.277 h(-1) and 0.248 h(-1), respectively; P <.01), indicative of slower intravascular-extravascular exchange for smaller LDL.",Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045696/),1/[h],0.248,215040,DB00175,Pravastatin
,22638872,passive diffusion,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],0.5,215573,DB00175,Pravastatin
,22638872,efflux intrinsic clearance,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],1.2,215574,DB00175,Pravastatin
,22638872,AUC ratio,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,4.4,215575,DB00175,Pravastatin
,22638872,Vs,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,10,215576,DB00175,Pravastatin
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,6.5,216135,DB00175,Pravastatin
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,7.9,216136,DB00175,Pravastatin
,27595040,mean residence time,"Microcapsules of f6 formulation achieved best performance regarding in vitro drug release and from pharmacokinetic evaluation mean residence time was found to be 6.3 h, thus indicated, Pravastatin Sodium microcapsules were released and absorbed slowly over a prolonged period of time.",Formulation and Pharmacokinetic Evaluation of Microcapsules Containing Pravastatin Sodium Using Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27595040/),h,6.3,220563,DB00175,Pravastatin
,24783509,m,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,453.3,221398,DB00175,Pravastatin
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,447.2,221399,DB00175,Pravastatin
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,327.4,221400,DB00175,Pravastatin
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,285.1,221401,DB00175,Pravastatin
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,192.9,221402,DB00175,Pravastatin
,8968530,CLuptake,"Among the tissues examined, liver accounted for the major uptake (CLuptake,liver = 22.8 mL min-1 kg-1), followed by kidney (CLuptake,kidney (GFR corrected) = 2.36 mL min-1 kg-1).",Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968530/),[ml] / [kg·min],22.8,222853,DB00175,Pravastatin
,8968530,CLuptake,"Among the tissues examined, liver accounted for the major uptake (CLuptake,liver = 22.8 mL min-1 kg-1), followed by kidney (CLuptake,kidney (GFR corrected) = 2.36 mL min-1 kg-1).",Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968530/),[ml] / [kg·min],2.36,222854,DB00175,Pravastatin
less,8968530,uptake,Other tissues showed no significant uptake (less than 0.2 mL min-1 kg-1).,Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968530/),[ml] / [kg·min],0.2,222855,DB00175,Pravastatin
,8968530,hepatic uptake ratio,The first-pass hepatic uptake ratio was estimated as 0.66.,Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968530/),,0.66,222856,DB00175,Pravastatin
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00175,Pravastatin
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00175,Pravastatin
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00175,Pravastatin
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00175,Pravastatin
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],384.2,223848,DB00175,Pravastatin
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],392.0,223849,DB00175,Pravastatin
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223850,DB00175,Pravastatin
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],96.0,223851,DB00175,Pravastatin
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],98.0,223852,DB00175,Pravastatin
,12395976,Cmax,"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223853,DB00175,Pravastatin
,12395976,C(max-DN10mg),These values were 7-8 times higher than the normalized value of C(max-DN10mg) for the control group (13.7 ng/ml).,Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],13.7,223854,DB00175,Pravastatin
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1228.2,223855,DB00175,Pravastatin
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1214.1,223856,DB00175,Pravastatin
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],345.9,223857,DB00175,Pravastatin
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],157.5,223858,DB00175,Pravastatin
,11850660,Bioavailability,"Bioavailability of SQ 31,906 was somewhat higher in the PM group (20% greater following PM administration), and urinary excretion of SQ 31,906 was significantly increased by 60% following PM dosing.",Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850660/),%,20,224176,DB00175,Pravastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,80,226815,DB00175,Pravastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,18,226816,DB00175,Pravastatin
>,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,95,226817,DB00175,Pravastatin
,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,60,226818,DB00175,Pravastatin
,8351718,initial steady state concentrations,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],400,227612,DB00175,Pravastatin
,8351718,AUC divided by dosing interval,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],550,227613,DB00175,Pravastatin
,8351718,trough levels,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],200,227614,DB00175,Pravastatin
,25666025,elimination half-life,"PVS has a short elimination half-life (1-3 h), suffers from instability at gastric pH, extensive hepatic first-pass metabolism and low absolute bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),h,1-3,230470,DB00175,Pravastatin
,25666025,absolute bioavailability,"PVS has a short elimination half-life (1-3 h), suffers from instability at gastric pH, extensive hepatic first-pass metabolism and low absolute bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),%,18,230471,DB00175,Pravastatin
,25666025,EE%,"The best achieved enteric surface-coated spanlastic dispersion (E-S6) displayed spherical nanosized vesicles (647.60 nm) possessing negative zeta potential (-6.93 mV), promising EE% (63.22%) and a biphasic drug-release pattern characterized by a retarded-release phase (0.1 N HCl, 2 h) and a controlled-release phase (pH 6.8, 10 h).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),%,63.22,230472,DB00175,Pravastatin
,22630116,Cmax,"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [ml],75.63,233004,DB00175,Pravastatin
,22630116,AUC(0-8),"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [h·ml],311.10,233005,DB00175,Pravastatin
,22630116,AUC(0-∞),"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [h·ml],909.42,233006,DB00175,Pravastatin
,22630116,Cmax,"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [ml],67.40,233007,DB00175,Pravastatin
,22630116,AUC(0-8),"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [h·ml],130.33,233008,DB00175,Pravastatin
,22630116,AUC(0-∞),"Pharmacokinetic studies in rabbits showed significantly higher (p < 0.05) Cmax (75.63 ± 6.98 ng/mL), AUC(0-8) (311.10 ± 5.89 ng/mL/h) and AUC(0-∞) (909.42 ± 5.89 ng/mL/h) than pravastatin oral tablet (Cmax - 67.40 ± 9.23 ng/mL, AUC(0-8)-130.33 ± 10.25 ng/mL/h and AUC(0-∞)-417.17 ± 5.89 ng/mL/h)).",Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22630116/),[ng] / [h·ml],417.17,233009,DB00175,Pravastatin
,11256847,terminal half-life,The terminal half-life is approximately 20 hours.,"Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11256847/),h,20,235034,DB00175,Pravastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB00175,Pravastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB00175,Pravastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB00175,Pravastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB00175,Pravastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB00175,Pravastatin
,19635387,limit of detection,The assay limit of detection was 0.2 ng mL(-1) and the effective working range at relative standard deviation (RSD) of <or=5% was 0.5-20 ng mL(-1).,New highly sensitive enzyme immunoassay for the determination of pravastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635387/),[ng] / [ml],0.2,245124,DB00175,Pravastatin
,19635387,analytical recovery,The mean analytical recovery of PRV from spiked plasma was 100.9+/-2.98%.,New highly sensitive enzyme immunoassay for the determination of pravastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19635387/),%,100.9,245125,DB00175,Pravastatin
,10226769,area under the plasma concentration vs. time curve (AUC0-infinity),"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[h·ng] / [ml],170,251936,DB00175,Pravastatin
,10226769,area under the plasma concentration vs. time curve (AUC0-infinity),"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[h·ng] / [ml],224,251937,DB00175,Pravastatin
,10226769,area under the plasma concentration vs. time curve (AUC0-infinity),"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[ng] / [ml],124,251938,DB00175,Pravastatin
,10226769,area under the plasma concentration vs. time curve (AUC0-infinity),"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[h·ng] / [ml],200,251939,DB00175,Pravastatin
,10226769,Cmax,"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[ng] / [ml],91,251940,DB00175,Pravastatin
,10226769,Cmax,"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[ng] / [ml],124,251941,DB00175,Pravastatin
,10226769,Cmax,"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[h·ng] / [ml],200,251942,DB00175,Pravastatin
,10226769,Cmax,"Pravastatin area under the plasma concentration vs. time curve (AUC0-infinity) and Cmax in the absence of mibefradil on day 1 (170 [117 to 395] ng h/mL and 91 [72 to 200] ng/mL respectively, geometric mean [95% confidence intervals]) were not significantly altered in the presence of mibefradil on day 8 (224 [174 to 381] ng h/mL and 124 [72 to 200] ng/mL) and on day 16 (200 [137 to 555] ng h/mL and 91 [74 to 184] ng/mL).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),[ng] / [ml],91,251943,DB00175,Pravastatin
,10226769,Tmax,"Tmax of pravastatin in the absence of mibefradil (0.9 +/- 0.1 h, arithmetic mean +/- SD) was slightly delayed in the presence of mibefradil on day 8 and 16 (1.1 +/- 0.3 and 1.2 +/- 0.3 h respectively, p < 0.01 for both comparisons).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),h,0.9,251944,DB00175,Pravastatin
,10226769,Tmax,"Tmax of pravastatin in the absence of mibefradil (0.9 +/- 0.1 h, arithmetic mean +/- SD) was slightly delayed in the presence of mibefradil on day 8 and 16 (1.1 +/- 0.3 and 1.2 +/- 0.3 h respectively, p < 0.01 for both comparisons).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),h,1.1,251945,DB00175,Pravastatin
,10226769,Tmax,"Tmax of pravastatin in the absence of mibefradil (0.9 +/- 0.1 h, arithmetic mean +/- SD) was slightly delayed in the presence of mibefradil on day 8 and 16 (1.1 +/- 0.3 and 1.2 +/- 0.3 h respectively, p < 0.01 for both comparisons).","Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10226769/),h,1.2,251946,DB00175,Pravastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],1.44,256262,DB00175,Pravastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],30.6,256263,DB00175,Pravastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],12.7,256264,DB00175,Pravastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],62.9,256265,DB00175,Pravastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],0.84-1.2,256266,DB00175,Pravastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],14-35,256267,DB00175,Pravastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],11-19,256268,DB00175,Pravastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],123-185,256269,DB00175,Pravastatin
,16678545,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of pravastatin in *1b/*1b carriers (47.4 +/- 19.9 ng.h/mL) was 65% of that in *1a/*1a carriers (73.2 +/- 23.5 ng.h/mL) (P = .049).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],47.4,257500,DB00175,Pravastatin
,16678545,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of pravastatin in *1b/*1b carriers (47.4 +/- 19.9 ng.h/mL) was 65% of that in *1a/*1a carriers (73.2 +/- 23.5 ng.h/mL) (P = .049).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],73.2,257501,DB00175,Pravastatin
,16678545,AUC,Carriers of *1b/*15 (38.2 +/- 15.9 ng.h/mL) exhibited a 45% lower AUC than *1a/*15 carriers (69.2 +/- 23.4 ng.h/mL) (P = .024).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],69.2,257502,DB00175,Pravastatin
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],12.4,257503,DB00175,Pravastatin
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],18.5,257504,DB00175,Pravastatin
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],16.4,257505,DB00175,Pravastatin
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],19.0,257506,DB00175,Pravastatin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00175,Pravastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00175,Pravastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00175,Pravastatin
,17080507,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 107.44 and 98.93% for pravastatin and IS, respectively.",A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),%,107.44,259228,DB00175,Pravastatin
,17080507,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 107.44 and 98.93% for pravastatin and IS, respectively.",A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),%,98.93,259229,DB00175,Pravastatin
,17080507,total run time,The method is simple and reliable with a total run time of 3 min.,A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080507/),min,3,259230,DB00175,Pravastatin
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00175,Pravastatin
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00175,Pravastatin
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00175,Pravastatin
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00175,Pravastatin
,15096102,elimination half-life,"After an intravenous injection of FNX (2 mg/kg), the plasma concentration time curves showed a profile of a two-compartment open model with an elimination half-life of 6.6 h.",Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096102/),h,6.6,269475,DB00175,Pravastatin
>,15096102,plasma protein binding,"In spite of high plasma protein binding (>99%), the V(d)beta was unusually large, 0.7 L/kg.",Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096102/),%,99,269476,DB00175,Pravastatin
,15096102,V(d)beta,"In spite of high plasma protein binding (>99%), the V(d)beta was unusually large, 0.7 L/kg.",Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096102/),[l] / [kg],0.7,269477,DB00175,Pravastatin
,16722833,half-life (t1/2),"The cardiac transplant recipients with the SLCO1B1 521TC genotype (n = 3) had a 46% lower Cmax (-67.7 ng ml(-1), 95% CI -135.7, 0.3; P = 0.055) and 62% lower AUC(0,24 h) (-228.5 ng ml(-1) h, 95% CI -402.7, -54.3; P = 0.016) and a shorter half-life (t1/2) (0.9 +/- 0.1 vs. 1.3 +/- 0.4 h, P = 0.015) of pravastatin than those with the reference genotype.",Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722833/),h,0.9,271587,DB00175,Pravastatin
,16722833,half-life (t1/2),"The cardiac transplant recipients with the SLCO1B1 521TC genotype (n = 3) had a 46% lower Cmax (-67.7 ng ml(-1), 95% CI -135.7, 0.3; P = 0.055) and 62% lower AUC(0,24 h) (-228.5 ng ml(-1) h, 95% CI -402.7, -54.3; P = 0.016) and a shorter half-life (t1/2) (0.9 +/- 0.1 vs. 1.3 +/- 0.4 h, P = 0.015) of pravastatin than those with the reference genotype.",Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722833/),h,1.3,271588,DB00175,Pravastatin
